Moderna, Inc. (MRNA) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup is a low bar on revenue — consensus sits at ~$105M vs. management's own Q2 guidance of $50–$100M, implying the street is already above the top of guidance — but the real story is cost execution and cash burn, where MRNA has consistently outperformed; the single biggest swing factor is whether management reiterates or tightens full-year revenue guidance heading into the critical fall COVID/flu season.

Heading into Q2 2026 results, Moderna faces its seasonally weakest quarter by design: management guided Q2 revenue to $50–$100M (evenly split US/international), a sharp step-down from Q1's $389M UK-partnership-driven beat, and consensus at ~$105M sits modestly above the top of that range. The bar on revenue is low — any delivery near the guidance midpoint would be in-line, and a beat would require either earlier-than-expected fall pre-orders or incremental partnership revenue. On the cost side, Moderna has beaten adjusted cash cost targets for four consecutive quarters, and the Q2 print will be watched for confirmation that the full-year $4.2B cash cost target remains intact. Guidance tone has been stable-to-constructive since the Q1 call: the June 25 Science Day reiterated no change to cash guidance, and the VRBPAC 9-0 vote on June 17 for mRNA-1010 flu vaccine materially de-risked the August 5 PDUFA date, which drove a sharp stock re-rating. Estimate revisions have been modestly positive — the Q2 EPS consensus improved ~3.7% over the past 90 days from -$2.14 to -$1.89 — but the stock has already rallied ~28% since the Q1 print, outperforming XBI (+16%) and SPY (+3%) by a wide margin, meaning much of the near-term good news is priced in. The wildcard is the August 5 flu PDUFA: an approval (widely expected post 9-0 VRBPAC vote) would be a catalyst for 2027 revenue estimates, while any delay or label restriction would be a meaningful negative surprise given how much the stock has re-rated on flu optionality.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus at ~$105M revenue is modestly above the top of management's $50–$100M Q2 guidance, making revenue a low bar; the bigger swing factor is operating cost execution and whether the full-year $4.2B cash cost target is reaffirmed, as that underpins the 2028 breakeven thesis.

Table 1 — Q2 2026 Current Quarter Snapshot (All Key KPIs)

Source: Visible Alpha Consensus & Actuals; Moderna Q1 2026 Earnings Call (May 1, 2026). Q2 2026 consensus as of July 30, 2026. Q1 2026 actual COGS inflated by $900M Arbutus litigation settlement charge; operating figures exclude this charge where noted.

Table 2 — Beat/Miss History: Last 8 Quarters (Top 2 KPIs)

KPI 1: Total Revenue ($M)

Pattern: MRNA has beaten revenue consensus in 7 of the last 8 quarters, with the sole miss in Q1 2025 (a seasonally weak quarter); the magnitude of beats is consistently large in Q2 and Q3 (fall vaccine season), driven by partnership delivery timing that the street consistently underestimates.

KPI 2: Operating EPS — Diluted ($)

Pattern: MRNA has beaten operating EPS consensus in 6 of the last 8 quarters; the two misses (Q1 2026 and Q4 2024) were driven by one-time charges (Arbutus litigation settlement) or higher-than-expected COGS, not underlying operational deterioration. The consistent EPS beat pattern reflects aggressive cost reduction outpacing street estimates.

Source: Visible Alpha Consensus & Actuals.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has been unchanged since the Q1 2026 earnings call (May 1), with the June 25 Science Day explicitly confirming "no change" to cash guidance; tone has shifted constructively on the flu regulatory pathway following the 9-0 VRBPAC vote, but management has not raised full-year revenue guidance despite the Q1 beat.

Source: Moderna Q1 2026 Earnings Call (May 1, 2026); Moderna Science Day transcript (June 25, 2026); Visible Alpha.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for Q2 2026 have improved modestly (+7% on revenue, +3.7% on EPS) since the Q1 print, tracking in line with unchanged guidance; FY 2026 revenue estimates are stable near the top of the "up to 10% growth" range, suggesting the street is giving management credit for the Q1 beat without extrapolating further upside — a balanced setup.

FY 2026 revenue estimates are essentially flat since the Q1 print, sitting at the top of management's "up to 10% growth" range (~$2.09B vs. ~$1.93B base), suggesting the street is not extrapolating further upside from the Q1 beat. FY 2027 estimates have ticked up modestly (+2%), likely reflecting incremental confidence in the flu launch (mRNA-1010) and EU market opening. The slight deterioration in FY 2026/2027 EPS estimates reflects higher-than-expected R&D spend trajectory (H2-weighted) rather than any revenue concern.

Source: Visible Alpha Consensus & Actuals; Moderna Q1 2026 Earnings Call (May 1, 2026). Post-earnings baseline as of May 6, 2026 (5 trading days post Q1 print).

5. Stock Performance

Key Takeaway: MRNA has surged +28% since the Q1 2026 earnings print (May 1), dramatically outperforming XBI (+16%) and SPY (+3%), driven almost entirely by multiple expansion on flu regulatory optionality (VRBPAC 9-0 vote, June 17) rather than estimate revisions — the stock re-rated sharply on the flu catalyst and has since partially given back gains, suggesting the market is now waiting for the August 5 PDUFA decision to confirm the next leg.

MRNA vs. XBI (SPDR S&P Biotech ETF) vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings Date (May 1, 2026). Source: Yahoo Finance / Stock Price Data.

The stock's performance since Q1 earnings has been almost entirely driven by the flu regulatory catalyst rather than earnings estimate revisions (which were modest, +3.7% on EPS over 90 days). The VRBPAC 9-0 vote on June 17 triggered a sharp re-rating as the market priced in a near-certain flu approval and the associated 2027 revenue uplift. The subsequent pullback from the July 6 peak of $81.80 to $57.92 (as of July 30) reflects profit-taking ahead of the Q2 print and the upcoming Arbutus lump-sum payment (~$900M due Q3), which will reduce the cash balance from $7.5B. At current levels, MRNA trades at ~1.0x FY 2026 consensus revenue, a modest premium to its pre-flu-catalyst multiple but well below pandemic-era peaks.

Source: Yahoo Finance / Stock Price Data. XBI (SPDR S&P Biotech ETF) used as sector benchmark, appropriate for MRNA's commercial-stage biotech classification.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the VRBPAC 9-0 vote for mRNA-1010 flu vaccine (June 17), which de-risked the August 5 PDUFA date and is the primary driver of the stock's re-rating; a flu approval would unlock 2027 revenue estimates and validate Moderna's diversification thesis.

• June 17, 2026 — VRBPAC Votes 9-0 in Favor of mRNA-1010 Flu Vaccine (Adults 50+): FDA's advisory committee voted unanimously that the benefits of mRNA-1010 outweigh risks for adults 50–64 and 65+. PDUFA date remains August 5, 2026. This is the single most important catalyst since Q1 earnings — a 9-0 vote is the strongest possible advisory signal and makes approval highly likely.
• Implication: Approval would make mRNA-1010 Moderna's fifth approved product and unlock 2027 flu revenue estimates. Management has guided no flu revenue in 2026 guidance, so any approval is additive to the 2027 story.
• June 25, 2026 — Moderna Science Day (Cambridge): Management confirmed "no change" to cash guidance and provided deep-dive on early pipeline (Horizon 2 and 3 programs). Key updates: mRNA-4359 showed 67% ORR in PD-L1+ checkpoint-refractory melanoma (9/9 patients); mRNA-1195 (EBV/MS therapeutic) DSMB cleared dose escalation; mRNA-607 (in vivo CAR-T) and mRNA-2151 (ovarian cancer T-cell engager) targeted for first-in-human by end of 2027.
• Implication: Science Day reinforced the pipeline depth narrative without changing near-term financial guidance — a net positive for sentiment.
• July 8, 2026 — Moderna Appoints Former Biogen CFO Michael McDonnell to Board: McDonnell brings deep biopharma financial and operational experience.
• Implication: Signals continued focus on financial discipline and cost management heading toward 2028 breakeven.
• July 9, 2026 — Q2 2026 Earnings Date Confirmed (July 31, 2026 BMO): Moderna confirmed earnings release before market open on July 31, 2026.
• May 1, 2026 — Q1 2026 Earnings: Large Revenue Beat, Arbutus Settlement Announced: Revenue of $389M beat consensus of $259M by ~50%, driven by UK strategic partnership deliveries. Arbutus litigation settled with $900M lump-sum payment due Q3 2026 and potential contingent payment pending Federal Circuit ruling. MMA registrational trial deferred pending PA readout.
• Implication: The Arbutus payment will reduce Q3 cash by ~$900M from Q1's $7.5B; investors will watch Q2 cash balance closely.
• May 11, 2026 — Moderna Amends Bylaws to Designate Federal Courts for Securities Claims: Routine governance update; no material financial impact.
• Competitive Landscape — BioNTech Restructuring: BioNTech announced plans to exit manufacturing sites in Idar-Oberstein, Marburg, and Singapore (affecting 1,800+ positions) and spin out its mRNA innovation programs into a new independent company.
• Implication: Validates Moderna management's thesis that it is now the only scaled mRNA company; reduces competitive pressure in the mRNA vaccine space.
• Eli Lilly Vaccine Market Entry (~May 2026): Lilly announced three vaccine acquisitions (Curevo for shingles, LimmaTech for bacterial pathogens, Vaccine Company for EBV) for up to ~$3.8B combined.
• Implication: Management characterized as validation of the vaccine space, not a competitive threat. Lilly's EBV entry is seen as further validation of Moderna's own EBV conviction.
• Analyst Rating Activity (Recent): Goldman Sachs (Jul 21), Morgan Stanley (Jul 8), RBC Capital (Jul 7), B of A Securities (Jul 7), and Piper Sandler (Jun 26) all maintained existing ratings — no upgrades or downgrades in the 60 days prior to earnings, suggesting the street is in a wait-and-see mode ahead of the Q2 print and August 5 PDUFA.

7. Peer Commentaries — Read-Through (Last 60 Days, Q2 2026 Relevant)

Key Takeaway: Peer commentary since Q1 earnings is broadly constructive for MRNA's Q2 setup: Pfizer confirmed stable European COVID vaccination rates and a market-leading US COVID position, BioNTech's Q1 results validated the COVID revenue seasonality pattern (H2-weighted), GSK's vaccine business growth and mRNA flu ambitions validate the flu market opportunity, and Merck's ASCO commentary on the Intismeran partnership was explicitly bullish on the program's potential.

Note: Only commentary from the current reporting period (Q2 2026) or post-Q1 2026 earnings (after May 1, 2026) is included below. Prior-quarter earnings commentary about prior-quarter results has been excluded.

BioNTech (BNTX) — Q1 2026 Earnings Call (May 5, 2026)

Read-Through Relevance: HIGH — BioNTech is Moderna's primary COVID vaccine competitor globally. Their Q1 2026 commentary provides direct read-through on COVID market dynamics heading into Q2 2026.

• COVID Revenue Seasonality Confirmed: BioNTech confirmed COVID vaccine revenue pacing "similar to last year's, with the last 4 months of the year driving the majority of the full year revenue figure." This directly validates Moderna's Q2 guidance of $50–$100M (seasonally weakest quarter) and supports the thesis that H2 2026 will be the revenue inflection point.
• European COVID Market: Stable but Transitioning: BioNTech guided to "lower revenues as we defend our market share and begin managing the transition away from multiyear contracts" in Europe. This is a read-through risk for Moderna — the EU COVID market is contracting as legacy contracts roll off, though Moderna's EU market opening (mNEXSPIKE, mCOMBRIAX) is a 2027 story, not 2026.
• US COVID Market: Competitive and Dynamic: BioNTech described the US market as "competitive and dynamic," consistent with Moderna's own commentary about potential vaccination rate softness. Pfizer/BioNTech holds >60% US market share, leaving Moderna competing for the remainder with mNEXSPIKE's efficacy differentiation.
• mRNA Oncology Validation: BioNTech's autogene cevumeran (personalized cancer vaccine, partnered with Roche) showed 7 of 8 immune responders still alive at 6 years in PDAC Phase I — strong mechanistic validation of the personalized mRNA cancer vaccine approach that underpins Moderna's Intismeran program.
• BioNTech Restructuring — Competitive Moat Widening: BioNTech announced plans to exit manufacturing sites (Idar-Oberstein, Marburg, Singapore, CureVac sites) affecting 1,800+ positions and spin out mRNA innovation into a new independent company. This validates Moderna management's thesis that MRNA is now the only scaled mRNA company, reducing long-term competitive pressure.

Pfizer (PFE) — Q1 2026 Earnings Call (May 5, 2026)

Read-Through Relevance: MEDIUM-HIGH — Pfizer's Comirnaty (COVID vaccine, partnered with BioNTech) competes directly with Moderna's Spikevax/mNEXSPIKE. Pfizer's commentary on COVID market dynamics and European vaccination rates is directly relevant to Moderna's Q2 and H2 2026 outlook.

• European COVID Vaccination Rates: Stable in 2025: Pfizer confirmed European vaccination rates in 2025 were "mostly stable versus 2024" — France at ~25% adult vaccination rate, Spain at ~35%. Governments are "willing to continue to invest and increase awareness" for older/at-risk populations.
• Read-through for MRNA: Stable EU vaccination rates support Moderna's 2026 international revenue guidance, though Moderna's EU COVID revenue is minimal in 2026 (market opening expected 2027).
• US COVID Market: Label Narrowing Caused Market Shrinkage: Pfizer noted a "narrowing of the label" for Comirnaty in the US led to "a shrinking of the market a bit." Pfizer maintains >60% US COVID market share.
• Read-through for MRNA: A smaller US COVID market is a headwind for Moderna's US revenue, though mNEXSPIKE's superior efficacy profile (targeting elderly) provides a differentiated positioning in the remaining market.
• UK Contract Absence Explains Pfizer Q1 COVID Decline: Pfizer's Q1 Comirnaty decline was attributed to the absence of the UK contract ("we shipped our last contract elements of our contract with the UK"). This is the mirror image of Moderna's Q1 beat — Moderna captured the UK partnership revenue that Pfizer no longer has.
• RSV Market: Pfizer Holds 84% US Share: Pfizer's Abrysvo holds 84% US RSV market share.
• Read-through for MRNA: Moderna's mRESVIA faces a dominant incumbent in the US RSV market; management has acknowledged RSV will not be a significant 2026 growth driver, consistent with Pfizer's market share data.

GSK — Q2 2026 Earnings Call (July 28, 2026)

Read-Through Relevance: MEDIUM — GSK's vaccine business commentary provides read-through on the broader respiratory vaccine market and the flu vaccine opportunity that Moderna is targeting with mRNA-1010.

• Vaccine Business Growing 8% in Q2 2026: GSK's vaccine sales grew 8% in Q2 2026, driven by Arexvy (RSV), meningitis vaccines, and Shingrix in Europe. Arexvy benefited from a two-year supply tender win in Australia.
• Read-through for MRNA: Healthy vaccine market growth validates the commercial opportunity for Moderna's respiratory portfolio. Australia tender dynamics are relevant given Moderna's strategic partnership with Australia.
• Vaccine Market Under "Short-Term Pressure" from COVID Hangover: GSK acknowledged the vaccine business is "under short-term pressure, frankly, because of politics in some locations and a post-COVID hangover."
• Read-through for MRNA: Validates Moderna's cautious tone on near-term COVID vaccination rates; the "post-COVID hangover" dynamic is a shared headwind across the sector.
• GSK Pursuing mRNA Flu Vaccine — Positive Phase 2 Data: GSK announced it will present "positive phase two results" for its mRNA flu vaccine at the upcoming OPTIONS meeting, targeting the older adult segment where "currently available flu vaccine effectiveness has varied from 20 to 60% over the past 15 flu seasons." GSK has "not previously competed" in the older adult flu segment.
• Read-through for MRNA: GSK's mRNA flu program is a medium-term competitive threat to Moderna's mRNA-1010, but GSK is still in Phase 2 while Moderna has a PDUFA date of August 5, 2026 — Moderna has a multi-year first-mover advantage in the mRNA flu space. GSK's entry also validates the market opportunity.
• Vaccine Business "Very Durable" with "High Barriers to Entry": GSK characterized the vaccine business as having "very high barriers to entry" in the medium-to-long term, with vaccines representing <1% of healthcare spending but generating ~19x return on investment.
• Read-through for MRNA: Supports Moderna's long-term positioning as a scaled mRNA vaccine platform company.

Merck (MRK) — ASCO Investor Event (June 1, 2026) & Goldman Sachs Healthcare Conference (June 9, 2026)

Read-Through Relevance: HIGH for oncology — Merck is Moderna's partner on Intismeran (mRNA-4157/V940), the personalized cancer vaccine in Phase 3 adjuvant melanoma. Merck's commentary on the program is the most direct external validation of Intismeran's commercial potential.

• Merck Calls Intismeran Partnership "Extremely Lucky" — ASCO (June 1): Dean Li (EVP, Merck Research Labs) stated at ASCO: "There is a possibility that for the first time after 30-40 years, there could be a cancer vaccine... And that's something that we're extremely lucky to be partnered with Moderna."
• Read-through for MRNA: Merck's public enthusiasm for the Intismeran partnership is a strong signal of internal conviction ahead of the Phase 3 interim analysis expected in 2026. This is the most bullish external commentary on Intismeran from any source.
• Moderna Technology "Differentiated" — Goldman Sachs (June 9): Dean Li stated: "I have to give enormous credit to our partners. Their technology is differentiated." He highlighted Moderna's ability to include "20-plus" or "30" neoantigens in a single vaccine as "critically important" — a capability that competitors cannot replicate with recombinant protein approaches.
• Phase 3 Melanoma Data "Thought-Provoking": Li described the Phase 2 melanoma data as "thought-provoking" and stated: "If we can repeat that in the Phase 3, I think it will move the field in a substantial way." He also highlighted the 5-year melanoma data as demonstrating "pretty durable" results with "no more injections."
• Read-through for MRNA: Merck's confidence in the Phase 3 interim analysis (expected 2026) is a significant positive signal. A positive interim would be a transformational catalyst for MRNA, as Intismeran is explicitly excluded from the 2028 breakeven model and would be additive upside.
• Merck Expanding INT to Earlier-Stage Disease: Li confirmed Merck is "focused where KEYTRUDA works in earlier stage" and that confidence in the melanoma data "led us to open up additional trials and even earlier stage in lung as well" — consistent with Moderna's announcement of the new Phase 3 in Stage I NSCLC.

AstraZeneca (AZN) — Q2 2026 Earnings Call (July 27, 2026)

Read-Through Relevance: LOW — AstraZeneca's Q2 2026 earnings contained minimal commentary relevant to Moderna's business. AZN noted seasonal demand patterns for Flumist (flu vaccine) and a recent vaccine launch in the US, but provided no specific commentary on COVID, mRNA vaccines, or Moderna.

• Seasonal Flu Vaccine Demand Patterns Noted: AZN CFO noted "seasonal demand patterns for lower margin medicines such as Flumist" will weigh on H2 gross margins.
• Read-through for MRNA: Confirms flu vaccine revenue is H2-weighted, consistent with Moderna's own commercial seasonality. No direct read-through on mRNA-1010 competitive dynamics.

8. Insider Transaction Activity

Key Takeaway: No open-market discretionary buys or sells stand out — all executive transactions since Q1 earnings are either 10b5-1 plan-driven sales (President Hoge, CLO Klinger, CFO Mock) or routine RSU vesting/option grants; the absence of any discretionary open-market buying or unusual selling is a neutral signal heading into earnings.

Summary: All executive transactions since Q1 earnings are either pre-planned 10b5-1 sales (Hoge, Klinger), routine RSU vesting with tax withholding (Mock, Hoge, Klinger), new director grants (McDonnell, Banque Soria), or annual equity grants. There are no open-market discretionary buys or unusual discretionary sells. The absence of any insider buying at current price levels (~$58) is a mild negative signal, but the consistent 10b5-1 plan activity from the President (Hoge) is not informative about near-term outlook. Overall: neutral.

Source: SEC Form 4 filings via Insider Transaction Data. Period covered: May 1, 2026 – July 30, 2026. Open-market buys (code P) and sells (code S) plus 10b5-1 plan initiations only; RSU vesting (code M/F) and grants (code A) included for context.